Scott Vandermeer
Gründer bei Infusion 51A LP
Aktive Positionen von Scott Vandermeer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Infusion 51A LP | Gründer | 01.04.2015 | - |
| Corporate Officer/Principal | 01.04.2015 | - | |
| International Infusion LP | Finanzdirektor/CFO | 01.04.2011 | - |
Vivacitas Oncology, Inc.
 Vivacitas Oncology, Inc. Medical/Nursing ServicesHealth Services Vivacitas Oncology, Inc. is a private clinical stage biopharmaceutical company founded in 2015 by Dr. Joseph Rubinfeld and Infusion 51a, LP. The company is based in Walnut Creek, CA. Vivacitas Oncology is focused on combating cancers that have proven to be resistant to current treatment modalities. The company aims to improve upon well-known chemotherapies with demonstrated effect, but which also possess challenges with potency, toxicity, stability, and other issues limiting their use. The CEO is Mark J. Suseck. | Direktor/Vorstandsmitglied | - | - |
| Finanzdirektor/CFO | - | - | |
| Gründer | 01.01.2015 | - |
Karriereverlauf von Scott Vandermeer
Ehemalige bekannte Positionen von Scott Vandermeer
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| AVANT DIAGNOSTICS INC | Vorstandsvorsitzender | 11.12.2017 | - |
| Finanzdirektor/CFO | 11.12.2017 | 01.01.2020 |
Ausbildung von Scott Vandermeer
| University of Illinois | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| 2 |
Operativ
| Director of Finance/CFO | 3 |
| Founder | 2 |
| Chief Executive Officer | 1 |
Sektoral
| Health Technology | 2 |
| Consumer Services | 2 |
| Miscellaneous | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Theralink Technologies, Inc. (Colorado)
 Theralink Technologies, Inc. (Colorado) Medical SpecialtiesHealth Technology Theralink Technologies, Inc. engages in the provision of biomarker assay services in the areas of oncology. The firm offers personalized medicine data through TheraLink assays to assist the biopharmaceutical industry and clinical oncologists in identifying drug treatments. It develops phosphoproteomic technologies that measure the activation status of signaling pathways. The company was founded on October 16, 2008 and is headquartered in Golden, CO. | Health Technology |
| Infusion 51A LP | Miscellaneous |
| International Infusion LP | |
Vivacitas Oncology, Inc.
Vivacitas Oncology, Inc. Medical/Nursing ServicesHealth Services Vivacitas Oncology, Inc. is a private clinical stage biopharmaceutical company founded in 2015 by Dr. Joseph Rubinfeld and Infusion 51a, LP. The company is based in Walnut Creek, CA. Vivacitas Oncology is focused on combating cancers that have proven to be resistant to current treatment modalities. The company aims to improve upon well-known chemotherapies with demonstrated effect, but which also possess challenges with potency, toxicity, stability, and other issues limiting their use. The CEO is Mark J. Suseck. | Health Services |
- Börse
- Insiders
- Scott Vandermeer
- Erfahrung
